Skip to main content
Clinical Trials/NCT02023762
NCT02023762
Completed
Not Applicable

Safety and Feasibility of Deep Sedation Instead of General Anaesthesia in Percutaneous Mitral Valve Repair Using the MitraClip® System

Heinrich-Heine University, Duesseldorf0 sites21 target enrollmentJanuary 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mitral Regurgitation
Sponsor
Heinrich-Heine University, Duesseldorf
Enrollment
21
Primary Endpoint
Number of patients with adverse Events
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

Percutaneous mitral valve repair (PMVR) with the MitraClip® system has emerged as a therapeutic alternative to surgical valve repair in patients who are at high risk and unsuitable for surgery. The PMVR procedure is typically performed under general anaesthesia, but the MitraClip® is also feasible in deep sedation.

The aim of this study is to investigate the safety of deep sedation in patients undergoing the PMVR procedure and to evaluate how deep sedation in comparison to general anaesthesia influences procedural time and in-hospital stay.

Detailed Description

Percutaneous mitral valve repair (PMVR) with the MitraClip® system has emerged as a therapeutic alternative to surgical valve repair in patients who are at high risk and unsuitable for surgery. The PMVR procedure, however, is typically performed under general anaesthesia. It has recently been shown in a first approach that performing the MitraClip® in deep sedation is feasible; however safety parameters and a direct comparison to general anaesthesia are still missing The aim of this study is to investigate the safety of deep sedation in patients undergoing the PMVR procedure and to evaluate how deep sedation in comparison to general anaesthesia influences procedural time and in-hospital stay.

Registry
clinicaltrials.gov
Start Date
January 2012
End Date
December 2013
Last Updated
12 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Heinrich-Heine University, Duesseldorf
Responsible Party
Principal Investigator
Principal Investigator

Klinik für Kardiologie, Pneumologie und Angiologie

Director Division of Cardiology, Pulmonary Disease and Vascular Medicine

Heinrich-Heine University, Duesseldorf

Eligibility Criteria

Inclusion Criteria

  • severe mitral regurgitation
  • PMVR using the MitraClip® system

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Number of patients with adverse Events

Time Frame: patients will be followed for the duration of procedure until discharge, an expected average of 10 days

Evaluation of feasibility and safety of deep sedation instead of general anaesthesia

Secondary Outcomes

  • Overall time to discharge(Participants will be followed for the duration of hospital stay, an expected average of 10 days)
  • Changes in 6-Minute Walk Test(Baseline to 1 month after intervention)
  • preparation and procedure time(procedure)
  • Changes in NYHA class(Baseline to 1 month after intervention)
  • Changes in N-terminal prohormone of brain natriuretic peptide (NT-proBNP)(Baseline to 1 month after intervention)

Similar Trials